The company reported a loss of $15.7 million, or 13 cents per share, marking a stark improvement from the $40.1 million loss recorded in the same period last year. Revenue reached $183.6 million, exceeding the $172.4 million consensus estimate from analysts polled by FactSet.

Following these results, the company raised its fiscal 2026 revenue guidance to a range of $710 million to $725 million, surpassing the previously forecasted $690 million to $710 million. Chief Executive Frank Leonard attributed the optimism to ongoing therapy launches across multiple global markets, asserting that the firm is positioned to drive sustainable growth toward long-term profitability. Year-to-date, the stock has gained 51%.